Skip to main content
. 2021 Feb 27;13(5):989. doi: 10.3390/cancers13050989
irAE immune related adverse event
ICI immune checkpoint inhibitor
mOS median overall survival
PD-1 programmed death 1
PD-L1 programmed death-ligand 1
CTLA-4 cytotoxic T-lymphocyte –associated protein 4
CNS central nervous system
RECIST Response Evaluation Criteria In Solid Tumors
CTCAE Common Terminology Criteria for Adverse Events
TPS tumor proportion score
NCCN National Comprehensive Cancer Network